News | November 16, 2025
Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
AI-powered cardiometabolic wellness platform for India’s workforce
The event will be attended by 35,000+ industry professionals
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
Subscribe To Our Newsletter & Stay Updated
